Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Background: Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose. If drug treatment is necessary, the drug of first choice is metformin. However, some people ca...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt, Norman Waugh
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: NIHR Journals Library 2017-01-01
Seri Bilgileri:Health Technology Assessment
Konular:
canagliflozin
dapagliflozin
empagliflozin
monotherapy
type 2 diabetes
systematic review
economic evaluation
sglt2 inhibitors
Online Erişim:https://doi.org/10.3310/hta21020

Internet

https://doi.org/10.3310/hta21020

Benzer Materyaller